Saving changes...

Done

Error

Rotavirus amongst Infants & Children

Rotavirus amongst Infants & Children

Rotavirus amongst Infants & Children

Medical Education Systems, Inc.
Medical Education Systems, Inc.
on behalf of Medical Education Systems Inc

$30.00 $ 30.00 $ 30.00

$30.00 $ 30.00 $ 30.00

$ 30.00 $ 30.00 $ 30.00
$ 30.00 $ 30.00 $ 30.00
Normal Price: $30.00 $30.00

Review:

Launch date: 30 Jun 2016
Expiry Date:

Last updated: 19 Mar 2018

Reference: 163424

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

Description

Rotavirus is the most common cause of severe gastroenteritis in infants and young children worldwide. Rotavirus causes approximately half a million deaths each year among children aged <5 years, with >80% of deaths occurring in developing countries ( 1). In the United States during the prevaccine era, rotavirus gastroenteritis resulted in relatively few childhood deaths (approximately 2060 deaths per year among children aged <5 years) ( 2--5). However, before initiation of the rotavirus vaccination program in 2006, nearly every child in the United States was infected with rotavirus by age 5 years; the majority had gastroenteritis, resulting annually during the 1990s and early 2000s in approximately 410,000 physician visits, 205,000272,000 emergency department (ED) visits, 55,00070,000 hospitalizations, and total annual direct and indirect costs of approximately $1 billion ( 5--9) ( Figure 1). This report presents the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of two rotavirus vaccines among U.S. infants: RotaTeq® (RV5) (Merck and Company, Whitehouse Station, New Jersey), which was licensed by the Food and Drug Administration (FDA) in February 2006 ( 10 ) and Rotarix® (RV1) (GlaxoSmithKline [GSK] Biologicals, Rixensart, Belgium), which was licensed by FDA in April 2008 (11 ). This report updates and replaces the 2006 ACIP statement for prevention of rotavirus gastroenteritis ( 12 ).

Objectives

Upon successful completion of this course, you will be able to:
* Define "Rotavirus" and identify how it is the most common cause of severe gastroenteritis in pediatric patients
* Identify how rotavirus is diagnosed
* List the current treatment protocols for rotavirus
Medical Education Systems, Inc.

Author Information Play Video Bio

Medical Education Systems, Inc.
on behalf of Medical Education Systems Inc

Medical Education Systems, Inc. provides home study courses and contact hours (CEU's) for EMTs, Nurses, Respiratory Therapists, Sleep Therapists, and other healthcare professionals. We understand that every profession has different requirements for contact hours as set forth by your professional society and your state board requirements.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • California Board of Registered Nursing (CBRN)
  • 5.00 Hours
  • Florida Board of Nursing
  • 5.00 Hours -
    Exam Pass Rate: 70
  • District of Columbia Board of Nursing (DCBON)
  • 5.00 Hours

Faculty and Disclosures

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error